BioSpace News Archive

PharmaDrug Inc. (CSE: PHRX) (OTC Pink: LMLLF) (“PharmaDrug” or the “Company”), a specialty pharmaceutical company focused on the research, development and commercialization of controlled-substances, natural medicines

Trinity Biotech plc a commercial stage biotechnology company focused on human diagnostics and diabetes management solutions, including wearable biosensors, announced that it has received substantial additional orders for TrinScreen HIV, bringing total orders received to date for supply in 2024 to approximately $6 million.

Applied DNA Sciences, Inc. and the Institute of Hematology and Blood Transfusion today announced that an abstract relating to the development of a fully enzymatic, non-viral manufacturing workflow to enable the rapid and cost-effective production of clinical-grade CAR T-cell therapies has been accepted for presentation at the prestigious European Hematology Association 2024 Hybrid Congress to be held in Madrid, Spain from June 13 - 16, 2024.

Cytokinetics Announces Primary Results From SEQUOIA-HCM Presented in Late Breaking Clinical Trial Session at the European Society of Cardiology Heart Failure 2024 Congress.

According to recent study by nova one advisor, the U.S. next generation sequencing market size was estimated at USD 4.10 billion in 2023 and is expected to be worth around USD 25.71 billion by 2033 with a CAGR of 20.15% from 2024 to 2033.

Incyte Corporation announced that its Board of Directors approved a share repurchase authorization of $2.0 billion.

Ajax Therapeutics, Inc., a biopharmaceutical company developing next generation JAK inhibitors for patients with myeloproliferative neoplasms, announced the closing of an oversubscribed $95 million Series C financing.

Moderna, Inc., announced its participation in the following upcoming investor conferences:

Aurora Spine Corporation, a designer and manufacturer of innovative medical devices that improve spinal surgery outcomes, announced it has scheduled a conference call to update investors and discuss its first quarter fiscal 2024 financial results that ended March 31, 2024.

Milestone Pharmaceuticals Inc. reported financial results for the first quarter ended March 31, 2024 and provided a regulatory and corporate update.